市場調查報告書
商品編碼
1279069
2022-2029年全球肝病治療市場規模研究與預測,按治療類型、疾病類型(肝炎、自身免疫性疾病、非酒精性脂肪肝、癌症、遺傳性疾病、其他)及區域分析Global Liver Disease Treatment Market Size study & Forecast, by Treatment Type, by Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, Others) and Regional Analysis, 2022-2029 |
肝臟是一個重要的器官,唯一功能是處理和消除潛在的有害身體毒素。任何引起肝臟炎症並可能阻礙肝臟正常功能的疾病狀況都被稱為肝病。肝臟問題可由感染、自身免疫性疾病、過度使用非處方藥、受傷、飲酒和其他因素引起。免疫球蛋白也用來治療某些類型的肝炎。飲酒和不健康的生活方式是導致全球非酒精性脂肪肝(NAFLD)、肝硬化、肝炎和肝癌等肝臟疾病患病率上升的主要原因。此外,世界各地老年人口的增加也導致了疾病的功能障礙。因此,因遺傳性基因疾病和上述不同的肝病而入院的人數激增。此外,不良的飲食習慣和不健康的飲食習慣導致體重過重,進一步導致肥胖症。導致成人脂肪肝的兩個主要因素是肥胖和酗酒。由於超重或肥胖,肝臟中出現脂肪。這導致了持續的炎症和肝臟疤痕(也稱為肝硬化)。肥胖和非酒精性脂肪肝是密切相關的。過多的脂肪會導致胰島素抵抗和炎症信號。高血壓、高膽固醇、體重過重、糖尿病或胰島素抵抗的患者更容易患脂肪肝。
此外,由於免疫水準比成年人低,老年群體更容易患肝病。此外,老齡化已被證明會增加對急性肝損傷的脆弱性。因此,在預測期內,老齡人口的增加預計將支持市場成長。根據世界銀行的數據,2015年世界上65歲及以上人口總數的8%,2021年該比例達到10%。此外,為開發更好的肝病治療方法而進行的研發活動投資不斷增加,預計將在預測期內為市場創造一個有利可圖的機會。然而,與肝病治療藥物和疫苗有關的嚴格的監管審批,在2022-2029年的預測期內抑制了市場成長。
全球肝病治療市場研究的主要地區包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。北美是全球市場佔有率的主導地區,這是因為該地區有主要的參與者,酒精消費的增加,不健康的生活方式導致肥胖和體重增加,以及醫療支出的增加。同時,由於研發活動的增加、肝臟疾病的激增、未得到滿足的醫療需求以及醫療部門投資的成長等因素,預計亞太地區將在預測期內表現出最高的成長率,這將為整個亞太地區的肝病治療市場創造有利的成長前景。
該研究的目的是確定近年來不同領域和國家的市場規模,並對未來幾年的價值進行預測。本報告旨在將研究涉及的國家內的產業的品質和數量方面都涵蓋其中。
本報告還提供了關於關鍵方面的詳細資訊,如驅動因素和挑戰,這將確定市場的未來成長。此外,它還涵蓋了微觀市場的潛在機會,供利益相關者投資,並詳細分析了競爭格局和主要參與者的產品。
Global Liver Disease Treatment Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. The liver is a crucial organ whose sole function is to process and eliminate potentially harmful body toxins. Any disease condition that causes liver inflammation and may impede the liver's normal function is referred to as liver disease. Liver problems can be caused by infections, autoimmune disorders, using over-the-counter medications excessively, getting injured, drinking alcohol, and other factors. Immunoglobulin is also used to treat certain types of hepatitis. Alcohol consumption and an unhealthy lifestyle are the main causes of the rising prevalence of liver disorders such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, and liver cancer worldwide. Additionally, an increase in elderly population around the world contributes to disease dysfunction. As a result, there has been an upsurge in hospital admissions for both hereditary genetic disorders and the different liver diseases indicated above. In addition, poor eating habits and unhealthy diet causes excess weight further leading to obesity. The two main factors contributing to fatty liver disease in adults are obesity and alcoholism. As a result of being overweight or obese, fat develops in the liver. This results in persistent inflammation and liver scarring (also known as cirrhosis). Obesity and non-alcoholic fatty liver disease are closely related. Excess fat leads to insulin resistance and inflammatory signals. Patients with high blood pressure, high cholesterol, excess body weight, diabetes, or insulin resistance are more susceptible to developing fatty liver disease.
Furthermore, owing to low immunity levels than adults, the geriatric population is more prone to liver illnesses. In addition, ageing has been shown to increase vulnerability to acute liver injury. Thus, the rising aging population is anticipated to support market growth during the forecast period. According to the World Bank, 8% of the total population aged 65 and older lived in the world in 2015, and in 2021 the rate reached 10 %. Additionally, the rising investments in R&D activities for the development of better liver disease treatment are anticipated to create a lucrative opportunity for the market during forecast period. However, the stringent regulatory approvals related to liver disease treatment drugs and vaccines stifle market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Liver Disease Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key players, rise in consumption of alcohol, unhealthy lifestyle leading to obesity & weight gain, and rise in healthcare expenditure in the region. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as increase in R&D activities, surge in liver diseases, unmet medical demands, and growing investments in the healthcare sector which would create lucrative growth prospects for the Liver Disease Treatment market across Asia Pacific region.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable